Redeye provides its initial take on Heliospectra’s Q3 results, which were largely in line with expec...
* Sales in-line with CTT's guidance, EBIT below ABGSCe * Removed Q4 guidance due to increased short-...
* Sales +1% and adj. EBITA +29% vs ABGSCe * Strong within defence and cybersecurity * Consensus EBIT...
Redeye expected a bit more from the Q3 report which showed lower sales and earnings than we anticipa...
* Sales +13% and adj. EBIT +39% vs. ABGSCe * Order intake SEK 224m, in line with ABGSCe * Likely pos...
Redeye comments on CombinedX’s Q3 report showing roughly flat organic growth and a solid rebound in ...
Redeye provides an initial comment on Safeture’s Q3 2025 report, where the company delivered a seque...
Redeye provides an initial comment on the Q3 2025 report from Sdiptech, where adjusted EBITA came in...
Redeye provides its initial take on Lagercrantz’s Q2 2025/2026 report, which featured an EBITA that ...
Redeye comments on Sleep Cycle’s Q3 report, which was in line with expectations.
Redeye updates its view on Nanologica following what we view as an undramatic Q3 2025 report.
Net sales and adj. EBIT were slightly below market consensus (LSEG) in Q3.
Redeye comments on Hexatronic’s Q3 report, beating our expectations thanks to strong development in ...
Redeye returns with a more in-depth take on the Q3 report.
Redeye reviews Alligator Bioscience’s Q3 report 2025.
Atria's Q3 2025 was strong with a 3% top line and 7% adjusted EBIT beat against LSEG Data & Analytic...
Redeye updates on Evolution after Q3 results that came in below expectations, owing to renewed weakn...
Redeye provides its initial take on MedCap’s Q3 2025 report, which came in broadly above our estimat...
* Small negative sales estimate revisions * Long term outlook is encouraging * Reiterate fair value ...
Hyresintäkterna steg med 45% till 15,5 meur och förvaltningsresultat ökade med 48% till 8,2 meur i d...
